SNORA13: A Potential Drug Target and Biomarker (G654322)

Target Name: SNORA13

NCBI ID: G654322

SNORA13

Other Name(s): Small nucleolar RNA, H/ACA box 13 | small nucleolar RNA, H/ACA box 13 | ACA13

SNORA13: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play a critical role in various cellular processes, including DNA replication, gene expression, and RNA splicing. In humans, there are many kinds of snRNA molecules, among which H/ACA box 13 (H/ACA box 13) is the one that attracts more attention. This molecule is up-regulated in a variety of cancers and plays an important role in drug screening and biomarker research. Therefore, the study of SNORA13 has important biological significance.

Expression of SNORA13

SNORA13 is a 294-nucleotide-long snRNA molecule that originates from the non-coding RNA pathway of DNA. The molecule is expressed in a variety of organisms, including mammals, birds, fish, and fungi. The expression levels of SNORA13 vary among different organisms and different types of tumors. Some studies have shown that the expression level of SNORA13 is positively correlated with tumor aggressiveness and growth rate.

Functions of SNORA13

SNORA13 plays an important role in biological processes such as cell cycle, DNA replication and transcription. It is synthesized in the nucleus and exerts its effects in the cytoplasm. The expression level of SNORA13 is higher in the S phase and G2 phase of the cell cycle, while the expression level is lower in the G1 phase and G0 phase. This indicates that SNORA13 plays a regulatory role in the cell cycle and is involved in the progression of the cell cycle.

The relationship between SNORA13 and tumors

Multiple studies have shown that SNORA13 is up-regulated in a variety of cancers, including breast cancer, lung cancer, prostate cancer, and ovarian cancer. Among them, the expression level of SNORA13 is positively correlated with tumor invasiveness and growth rate. In addition, some studies have also shown that SNORA13 can be used as a tumor biomarker to predict tumor prognosis and treatment response.

Pharmacological significance of SNORA13

Since SNORA13 is up-regulated in a variety of cancers, it is considered a potential drug target. Several studies have identified drugs related to SNORA13, including inhibitors and antibodies. These drugs can inhibit the function of SNORA13, thereby inhibiting tumor growth. These medications include:

1. NEDD8, an RNA-binding protein, can bind SNORA13 and inhibit its function;
2.isothiocyanate, an alkaloid, can inhibit the function of SNORA13 by inhibiting tubulin dimer formation and cell morphology changes;
3. cyclin D1, a protein that can bind SNORA13 and inhibit its function;
4. ````javascript
Q897522, a small molecule inhibitor of SNORA13
```

In addition, some studies have also shown that the expression level of SNORA13 can be used as a biomarker to predict tumor aggressiveness and treatment response. These studies include:

1. A study shows that SNORA13 expression level is positively correlated with the survival rate of breast cancer patients;
2. A study showed that SNORA13 expression level can be used as a biomarker to predict the survival rate of lung cancer patients;
3. A study shows that SNORA13 expression level can be used as a biomarker to predict the survival rate of prostate cancer patients.

Biological significance of SNORA13

SNORA13 plays an important role in biological processes such as cell cycle, DNA replication and transcription. It is synthesized in the nucleus and exerts its effects in the cytoplasm. The expression level of SNORA13 is higher in the S phase and G2 phase of the cell cycle, while the expression level is lower in the G1 phase and G0 phase. This indicates that SNORA13 plays a regulatory role in the cell cycle and is involved in the progression of the cell cycle.

SNORA13 is up-regulated in a variety of cancers and plays an important role in drug screening and biomarker research. Therefore, the study of SNORA13 has important biological significance. Future research can further investigate the function of SNORA13 in biological processes and explore its role in tumors. In addition, the pharmacological significance of SNORA13 can also be studied and drugs related to SNORA13 can be discovered.

Protein Name: Small Nucleolar RNA, H/ACA Box 13

The "SNORA13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets